Arcturus Therapeutics Holdings, Inc. (ARCT)
8.02
+0.05
(+0.63%)
USD |
NASDAQ |
Nov 18, 16:00
8.02
0.00 (0.00%)
After-Hours: 20:00
Arcturus Therapeutics Holdings Enterprise Value : 63.88M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 63.88M |
| November 16, 2026 | 73.56M |
| November 13, 2026 | 74.98M |
| November 12, 2026 | 77.26M |
| November 11, 2026 | 102.02M |
| November 10, 2026 | 104.30M |
| November 09, 2026 | 107.14M |
| November 06, 2026 | 131.62M |
| November 05, 2026 | 103.44M |
| November 04, 2026 | 146.42M |
| November 03, 2026 | 108.57M |
| November 02, 2026 | 107.14M |
| October 30, 2026 | 150.97M |
| October 29, 2026 | 182.85M |
| October 28, 2026 | 180.57M |
| October 27, 2026 | 156.66M |
| October 26, 2026 | 119.10M |
| October 23, 2026 | 117.10M |
| October 22, 2026 | 142.43M |
| October 21, 2026 | 152.11M |
| October 20, 2026 | 149.55M |
| October 19, 2026 | 133.61M |
| October 16, 2026 | 131.33M |
| October 15, 2026 | 157.80M |
| October 14, 2026 | 153.53M |
| Date | Value |
|---|---|
| October 13, 2026 | 179.43M |
| October 12, 2026 | 195.94M |
| October 09, 2026 | 228.10M |
| October 08, 2026 | 203.34M |
| October 07, 2026 | 200.35M |
| October 06, 2026 | 207.04M |
| October 05, 2026 | 254.29M |
| October 02, 2026 | 207.89M |
| October 01, 2026 | 213.02M |
| September 30, 2026 | 226.68M |
| September 29, 2026 | 220.85M |
| September 28, 2026 | 242.45M |
| September 25, 2026 | 225.11M |
| September 24, 2026 | 232.78M |
| September 23, 2026 | 209.48M |
| September 22, 2026 | 240.17M |
| September 21, 2026 | 248.98M |
| September 18, 2026 | 287.07M |
| September 17, 2026 | 312.65M |
| September 16, 2026 | 274.85M |
| September 15, 2026 | 281.67M |
| September 14, 2026 | 266.04M |
| September 11, 2026 | 250.12M |
| September 10, 2026 | 228.80M |
| September 09, 2026 | 250.40M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.261B |
| Emergent BioSolutions, Inc. | 624.59M |
| Ionis Pharmaceuticals, Inc. | 4.776B |
| United Therapeutics Corp. | 22.69B |
| Ocugen, Inc. | 261.06M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.414M |
| Revenue (Quarterly) | 16.85M |
| Total Expenses (Quarterly) | 24.27M |
| EPS Diluted (Quarterly) | -0.2607 |
| Gross Profit Margin (Quarterly) | 96.44% |
| Profit Margin (Quarterly) | -43.99% |
| Earnings Yield | -38.41% |
| Normalized Earnings Yield | -36.96 |